Last reviewed · How we verify
ombitasvir/paritaprevir/ritonavir, dasabuvir
ombitasvir/paritaprevir/ritonavir, dasabuvir is a Small molecule drug developed by AbbVie. It is currently in Phase 3 development. Also known as: Viekira PAK, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450, dasabuvir also known as ABT-333.
At a glance
| Generic name | ombitasvir/paritaprevir/ritonavir, dasabuvir |
|---|---|
| Also known as | Viekira PAK, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450, dasabuvir also known as ABT-333 |
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment (PHASE4)
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (PHASE3)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- Study of Oral Treatments for Hepatitis C (PHASE4)
- Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ombitasvir/paritaprevir/ritonavir, dasabuvir CI brief — competitive landscape report
- ombitasvir/paritaprevir/ritonavir, dasabuvir updates RSS · CI watch RSS
- AbbVie portfolio CI
Frequently asked questions about ombitasvir/paritaprevir/ritonavir, dasabuvir
What is ombitasvir/paritaprevir/ritonavir, dasabuvir?
ombitasvir/paritaprevir/ritonavir, dasabuvir is a Small molecule drug developed by AbbVie.
Who makes ombitasvir/paritaprevir/ritonavir, dasabuvir?
ombitasvir/paritaprevir/ritonavir, dasabuvir is developed by AbbVie (see full AbbVie pipeline at /company/abbvie).
Is ombitasvir/paritaprevir/ritonavir, dasabuvir also known as anything else?
ombitasvir/paritaprevir/ritonavir, dasabuvir is also known as Viekira PAK, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450, dasabuvir also known as ABT-333.
What development phase is ombitasvir/paritaprevir/ritonavir, dasabuvir in?
ombitasvir/paritaprevir/ritonavir, dasabuvir is in Phase 3.
Related
- Manufacturer: AbbVie — full pipeline
- Also known as: Viekira PAK, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450, dasabuvir also known as ABT-333
- Compare: ombitasvir/paritaprevir/ritonavir, dasabuvir vs similar drugs
- Pricing: ombitasvir/paritaprevir/ritonavir, dasabuvir cost, discount & access